Abstract 1162
Background
Platinum and etoposide with concurrent thoracic radiation is the standard treatment for LS-SCLC. Elderly pts are common, and may experience higher rates of adverse events (AEs) and have a worse outcome from this treatment.
Methods
IPD were collected from 11 phase 2 or 3 trials for LS-SCLC conducted by the US National Cancer Institute-supported cooperative groups activated from 1990 to 2010. Overall survival (OS), progression-free survival (PFS) and AEs were compared between pts age ≥ 70 years (elderly) and for pts < 70 years (younger). Unadjusted and adjusted hazard ratios (HRs) for survival time and CIs were estimated by univariate and multivariable frailty Cox models.
Results
IPD from 1049 younger and 254 elderly pts were analyzed. In the univariate and multivariable models, elderly pts compared with younger pts had worse OS (HR of 1.40; 95% CI, 1.20 to 1.65 and 1.36; 95% CI, 1.15 to 1.59). Median OS in elderly and younger pts was 17.8 months and 23.5 months, respectively. In the univariate and multivariable models, elderly pts had worse PFS (HR of 1.23; 95% CI, 1.06 to 1.43 and 1.19; 95% CI, 1.03 to 1.39). Median PFS in elderly and younger pts was 10.6 and 12.3 months, respectively. Elderly and younger pts had a similar rates of all grade ≥ 3 AEs, but elderly pts had a statistically significantly higher rate of all grade ≥ 4 AEs (p < 0.01), hematologic ≥ 4 AEs (p < 0.01), and grade 5 AEs (8% vs 3%, p < 0.001). When specific AEs were analyzed, elderly pts experienced a higher rate of grade ≥ 3 dyspnea (p = 0.03), but a lower rate of grade ≥ 3 vomiting (p = 0.01) and esophagitis (p = 0.03). Elderly pts compared with younger pts completed treatment at a lower rate (p = 0.02), stopped treatment at higher rates due to adverse events (p = 0.02), patient refusal (p < 0.01), and death during treatment (p < 0.01).
Conclusions
Elderly pts with LS-SCLC experienced a worse PFS and OS, and experienced a statistically higher rate of grade 4 and 5 adverse events. Future trials should investigate methods to identify vulnerable elderly pts and reduce the toxicity of treatment.
Clinical trial identification
Legal entity responsible for the study
Tom Stinchcombe and Xiaofei Wang.
Funding
NIH grant: R21-AG042894.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract